For NEW Patient Copay Assistance information, please click on this link
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®Get your patients started on AJOVY. Begin here
The post hoc analyses from the long-term open-label extension study evaluated: the mean number of weekly migraine days during weeks 1-2 vs weeks 11-12, as well as the mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly and quarterly dosing. There was no evidence of “wearing off” throughout these time periods.1
For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.
See the dosing period data
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®